Clinical Trial Detail

NCT ID NCT03765918
Title Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

oral cavity cancer

larynx cancer

hypopharynx cancer

oropharynx cancer

Therapies

Pembrolizumab

Cisplatin + Pembrolizumab

Cisplatin

Age Groups: senior adult

No variant requirements are available.